Immunology of gynecologic neoplasms

Analysis of the prognostic significance of the immune status

F. Bellati, V. Visconti, C. Napoletano, M. Antonilli, L. Frati, P. Benedetti Panici, M. Nuti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.

Original languageEnglish
Pages (from-to)541-565
Number of pages25
JournalCurrent Cancer Drug Targets
Volume9
Issue number4
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Female Genital Neoplasms
Allergy and Immunology
Tumor-Infiltrating Lymphocytes
Therapeutics
Therapeutic Uses
Ovarian Neoplasms
Neoplasms
Vaccination
Survival Rate
Quality of Life
Research Personnel
Physicians
Antigens
Survival
Pharmaceutical Preparations
Population

Keywords

  • Gynecological cancer
  • Immune response
  • Immune signatures
  • Prognostic indicators
  • TAA

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Immunology of gynecologic neoplasms : Analysis of the prognostic significance of the immune status. / Bellati, F.; Visconti, V.; Napoletano, C.; Antonilli, M.; Frati, L.; Panici, P. Benedetti; Nuti, M.

In: Current Cancer Drug Targets, Vol. 9, No. 4, 06.2009, p. 541-565.

Research output: Contribution to journalArticle

Bellati, F. ; Visconti, V. ; Napoletano, C. ; Antonilli, M. ; Frati, L. ; Panici, P. Benedetti ; Nuti, M. / Immunology of gynecologic neoplasms : Analysis of the prognostic significance of the immune status. In: Current Cancer Drug Targets. 2009 ; Vol. 9, No. 4. pp. 541-565.
@article{ef5586861ab54516a3df44d4309f0f64,
title = "Immunology of gynecologic neoplasms: Analysis of the prognostic significance of the immune status",
abstract = "Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of {"}traditional{"} cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.",
keywords = "Gynecological cancer, Immune response, Immune signatures, Prognostic indicators, TAA",
author = "F. Bellati and V. Visconti and C. Napoletano and M. Antonilli and L. Frati and Panici, {P. Benedetti} and M. Nuti",
year = "2009",
month = "6",
doi = "10.2174/156800909788486722",
language = "English",
volume = "9",
pages = "541--565",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Immunology of gynecologic neoplasms

T2 - Analysis of the prognostic significance of the immune status

AU - Bellati, F.

AU - Visconti, V.

AU - Napoletano, C.

AU - Antonilli, M.

AU - Frati, L.

AU - Panici, P. Benedetti

AU - Nuti, M.

PY - 2009/6

Y1 - 2009/6

N2 - Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.

AB - Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.

KW - Gynecological cancer

KW - Immune response

KW - Immune signatures

KW - Prognostic indicators

KW - TAA

UR - http://www.scopus.com/inward/record.url?scp=67649402262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649402262&partnerID=8YFLogxK

U2 - 10.2174/156800909788486722

DO - 10.2174/156800909788486722

M3 - Article

VL - 9

SP - 541

EP - 565

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 4

ER -